Information
Welcome to the WOLTAM Consulting Frequently Asked Questions page. Here you'll find answers to common questions about our services, our approach, and how we can help your pharmaceutical business achieve compliant, measurable outcomes. We pride ourselves on providing expert, clear, and friendly advice, grounded in real-world experience and a commitment to practical, evidence-led solutions.
Frequently asked questions
We understand you have questions, and we're here to provide clarity. Our goal is to offer strategic clarity plus hands-on execution, underpinned by data and ABPI governance—so you can move faster, stay compliant, and deliver measurable impact. Below are answers to some of the most common questions we receive, categorised for your convenience.
Who are your ideal clients or customers within the pharmaceutical industry?
We work best with specialty pharma, biotech, and business units within large pharma that want compliant, measurable outcomes in 60–90 days. Typical partners include Brand/Franchise, Digital/Omnichannel, Medical/MLR (medical, legal, regulatory review), Market Access, Analytics, and Field Excellence teams, often at pre‑launch, indication expansion, post‑launch optimisation, or market entry. They value evidence-led strategy, modular MLR‑ready content, responsible AI workflows, and KPI dashboards that make it easy to scale what works.
What specific services do you offer for pharma and healthcare brands?
We offer a range of services tailored to the pharmaceutical industry, including strategic planning, omnichannel marketing, content creation, SEO/PPC (search engine optimization/pay-per-click) campaign management, and data analytics. Our services are designed to drive measurable results while adhering to ABPI/MLR guidelines. For a comprehensive overview, please visit our Our Services page.
How do you ensure content and campaigns are ABPI/MLR compliant?
We align with ABPI/MLR guidelines and incorporate privacy-by-design principles into all our projects. Our processes include thorough promotional review, risk mitigation strategies, and cross-functional alignment to ensure compliance. We have clear processes for promotional review, risk mitigation, and cross-functional alignment. Our advice reflects UK compliance and signatory workflows—practical guidance that survives approval. Compliance note: Marketing strategy only—no medical or clinical advice.
How do you approach non‑branded SEO for disease education?
Our approach to non-branded SEO (search engine optimization) for disease education involves careful keyword selection, high-quality content creation, and adherence to ethical SEO practices. We focus on providing valuable information to patients and healthcare professionals (HCPs) while ensuring compliance with regulations. Marketing strategy only—no medical or clinical advice.
How do you structure a 60–90 day pilot vs. a longer engagement?
A 60–90 day pilot is structured to deliver rapid, measurable outcomes. We focus on a specific objective, such as improving SEO or optimising a PPC (pay-per-click) campaign. Longer engagements allow for a more comprehensive approach, including strategic planning, content development, and ongoing optimisation. Timeline note: Discovery in 1 week; pilot in 2–4 weeks.
How do you measure content quality and HCP usefulness?
We measure content quality and HCP (healthcare professional) usefulness through a combination of quantitative and qualitative metrics. This includes tracking engagement metrics (e.g., time on page, bounce rate), gathering feedback from HCPs, and monitoring the impact on key performance indicators (KPIs). We track success using CVR (conversion rate), CPA (cost per acquisition), ROAS (return on ad spend), and time-to-approval.
Which KPIs matter most for pharma marketing?
The most important KPIs (key performance indicators) for pharma marketing include conversion rate (CVR), cost per acquisition (CPA), return on ad spend (ROAS), and time-to-approval. We also focus on metrics that reflect access wins, adherence, HCP quality interactions, and overall ROI (return on investment). Our data source of truth: GA4 (Google Analytics 4), GSC (Google Search Console), Ads (Google/Microsoft Ads), CRM (customer relationship management), and VoC (voice of customer).
What AI use cases are safe for pharma marketing?
Safe AI (artificial intelligence) use cases in pharma marketing include content optimisation, data analysis, and personalisation. We set governance, prompts, and human review for AI content. It’s important to have clear governance, prompts, and human review processes in place to ensure compliance and accuracy. We measure efficiency gains without risking compliance. Please contact us via the Contact page if you want to know more.
Ready to learn more?
Have more questions or ready to discuss how WOLTAM Consulting can help your pharmaceutical brand? Contact us today. We offer strategic clarity plus hands-on execution, underpinned by data and ABPI governance.
